Feb. 2, 2018
Bioceres S.A. (“Bioceres” or the “Company”), a fully-integrated provider of crop productivity solutions, including seeds, seed traits, seed treatments, biologicals, high-value adjuvants and micro-beaded fertilizers, announced the launch of its initial public offering of 11,818,182 ordinary shares, par value Ps. 1 per share, which may be represented by American Depositary Shares (“ADSs”), pursuant to a registration statement on Form F-1, as amended, filed with the U.S. Securities and Exchange Commission (the “SEC”). The initial public offering price is currently expected to be between US$10.00 and US$12.00 per ordinary share (US$10.00 and US$12.00 per ADS). The Company intends to grant the underwriters a 30-day option to purchase up to an additional 1,772,727 ordinary shares represented by ADSs at the initial public offering price, less underwriting discounts and commissions. The ADSs have been authorized for listing on the New York Stock Exchange under the ticker symbol “BIOX,” subject to official notice of issuance.
Jefferies is acting as sole global coordinator and Jefferies and Piper Jaffray are acting as joint book-running managers for the offering. Santander and SunTrust are also acting as joint book-running managers. Mirabaud Securities is acting as co-manager.
This offering will be made only by means of a prospectus. A copy of the preliminary prospectus can be obtained from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or by telephone at (877) 547-6340, or by email at Prospectus_Department@Jefferies.com; or Piper Jaffray & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402 or by telephone at 800-747-3924 or by email at firstname.lastname@example.org.
A registration statement relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time when the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
The public offering of the ordinary shares in Argentina was initially authorized by the Argentine Securities and Exchange Commission (Comisión Nacional de Valores) pursuant to Resolution No. 17919, dated December 4, 2015 and pursuant to Resolution No.19296 of January 18, 2018, subject to the fulfillment of certain requirements. Bioceres has also filed a petition for the authorization of listing its ordinary shares in Argentina in the Bolsas y Mercados Argentinos S.A. under the symbol “BIOX” but such authorization has not yet been granted.